4516N Stock Chart & Stats
$390.14
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range$388.24 - $418.43
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
$25.20B
Enterprise Value$200.69K
Total Cash (Recent Filing)$72.70B
Total Debt (Recent Filing)$2.56B
Price to Earnings (P/E)7.2
Beta-0.07
Next Earnings
Nov 18, 2026EPS Estimate
5.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)468.60
Shares Outstanding70,251,490
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.33
Price to Book (P/B)1.18
Price to Sales (P/S)2.02
P/FCF Ratio14.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$357.23Price Target Upside― Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)45.02
Revenue Forecast (FY)$20.88B
Bulls Say, Bears Say
Bulls Say
High MarginsSustained high gross, operating and net margins indicate durable pricing power and efficient cost structure typical of specialty pharma. These margins support ongoing R&D, cover commercialization costs, and provide a buffer against reimbursement or pricing pressures over months.
Very Low LeverageAn exceptionally conservative balance sheet with minimal debt materially lowers financial risk and preserves strategic optionality. This allows the company to fund R&D, pursue licensing or partnership deals, and absorb regulatory or market setbacks without near-term refinancing risk.
Specialty/partnering ModelConcentration in specialty and rare-disease therapeutics and an active licensing/partnering model create durable competitive advantages: higher margins, longer product lives, and milestone/royalty revenue streams that diversify income and support steady long-term cash generation.
Bears Say
Weaker Cash ConversionOperating cash flow lagging net income and a notable decline in free cash flow signal inconsistent cash conversion. This reduces predictability of internally funded R&D and dividends, raising the risk that working-capital swings or investment timing will constrain near-term reinvestment.
Margin CompressionA measurable decline in net margin versus the prior year suggests rising costs, less favorable mix, or pricing pressure. If persistent, margin compression would erode free cash flow and returns, limiting the firm's ability to expand commercial programs or fund new pipeline investments.
Negative EPS GrowthNegative EPS growth despite modest revenue gains implies profit-per-share deterioration from margin, one-time items, or capital structure effects. Over a multi-month horizon this undermines earnings momentum and could restrict capacity to increase dividends or finance strategic initiatives internally.
Nippon Shinyaku Co., Ltd. News
4516N FAQ
What was Nippon Shinyaku Co., Ltd.’s price range in the past 12 months?
Nippon Shinyaku Co., Ltd. lowest stock price was $388.24 and its highest was $418.43 in the past 12 months.
What is Nippon Shinyaku Co., Ltd.’s market cap?
Nippon Shinyaku Co., Ltd.’s market cap is $25.20B.
When is Nippon Shinyaku Co., Ltd.’s upcoming earnings report date?
Nippon Shinyaku Co., Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 66 days.
How were Nippon Shinyaku Co., Ltd.’s earnings last quarter?
Nippon Shinyaku Co., Ltd. released its earnings results on Aug 06, 2026. The company reported $15.953 earnings per share for the quarter, beating the consensus estimate of $10.515 by $5.438.
Is Nippon Shinyaku Co., Ltd. overvalued?
According to Wall Street analysts Nippon Shinyaku Co., Ltd.’s price is currently Undervalued.
Does Nippon Shinyaku Co., Ltd. pay dividends?
Nippon Shinyaku Co., Ltd. does not currently pay dividends.
What is Nippon Shinyaku Co., Ltd.’s EPS estimate?
Nippon Shinyaku Co., Ltd.’s EPS estimate is 5.68.
How many shares outstanding does Nippon Shinyaku Co., Ltd. have?
Nippon Shinyaku Co., Ltd. has 70,251,490 shares outstanding.
What happened to Nippon Shinyaku Co., Ltd.’s price movement after its last earnings report?
Nippon Shinyaku Co., Ltd. reported an EPS of $15.953 in its last earnings report, beating expectations of $10.515. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Nippon Shinyaku Co., Ltd.?
Currently, no hedge funds are holding shares in MX:4516N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Nippon Shinyaku Co., Ltd.
Nippon Shinyaku Co., Ltd., an enterprise established in Kyoto, Japan, in 1911, engages globally in the production and distribution of pharmaceutical products and functional foods. Its reach extends across Japan, Switzerland, and various international markets, with operations structured into two core divisions: Pharmaceuticals and Functional Food. The Pharmaceutical division concentrates on a wide array of therapeutic areas, encompassing conditions affecting the urinary system, inflammatory and allergic responses, hematologic malignancies, cardiovascular and metabolic disorders, gastrointestinal issues, and other diverse diseases. Its extensive product catalog features notable treatments such as Zalutia, designed for urinary difficulties arising from benign prostatic hypertrophy; Eviprostat, also for prostatic hypertrophy; Bladderon for frequent urination; and Estracyt, targeting prostate cancer. For erectile dysfunction, it provides Cialis. In hematology and oncology, the company's portfolio includes Vidaza for myelodysplastic syndrome; Cylocide and CylocideN for solid tumors, acute leukemia, and malignant lymphoma; Gazyva, a humanized anti-CD20 monoclonal antibody; Defiterio for sinusoidal obstruction syndrome; and Trisenox and Amnolake for relapsed and refractory acute promyelocytic leukemia. Nippon Shinyaku also offers Uptravi, Adcirca, and Opsumit for the management of pulmonary arterial hypertension, alongside VILTEPSO for muscular dystrophy. Other specialized medications include Lunabel LD and Lunabel ULD for dysmenorrhea; Erizas, a dry powder inhaler for allergic rhinitis; Azunol Gargle liquid, an azulene-based gargling solution; Isobide for oral osmotic diuresis and Meniere's disease; Cephadol for vertigo; Livostin for allergic rhinitis and conjunctivitis; Regtect, aimed at maintaining alcohol abstinence; and Onetram and Tramal for the treatment of cancer and chronic pain. Furthermore, the company actively conducts research, development, and marketing efforts in the fields of gynecology, otorhinolaryngology, and orthopedics. The Functional Food segment broadens the company's offerings, supplying various health-focused ingredients, food preservatives, protein preparations, dietary supplements, and a selection of spices and condiments.
4516N Stock 12 Month Forecast
Average Price Target
$357.23